Given the well-described hypermethylated phenotype hallmark of IDH-mut malignancies, DNA demethylating agents, capable of inducing long-term epigenetic reprogramming, were among the first therapeutic approaches investigated for treating those cancers. Here, IDH2 is linked to cancer.